STEVEN CESSNA: Open Payments
NPI 1346750916 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$397 in 20 payments from 10 companies in 2025. Trend: 2023 $523 · 2024 $251 · 2025 $397
Food & beverage: $397
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 3 | $70 |
| E.R. Squibb & Sons, L.L.C. | 3 | $50 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| Indivior Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $27 |
| Braeburn Inc. | 1 | $23 |
| ABBVIE INC. | 1 | $18 |
Products named: INVEGA SUSTENNA, COBENFY, INGREZZA, CAPLYTA, REXULTI, SUBLOCADE, Auvelity, BRIXADI.
Industry payments across LA — which companies pay providers there.
